|
|
|
LifeScienceHistory.com - Check us out on Instagram
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Axsome Therapeutics, Inc.
| | | Phone: | (212) 332-3241 | Fax: | (212) 320-0245 | Year Established: | 2012 | Ticker: | AXSM | Exchange: | NASDAQ | Main Contact: | Mark Jacobson, Senior VP, Operations | | Other Contacts: | Robert Niecestro, PhD, VP, Clinical and Regulatory Cedric O’Gorman, MD, MBA, Senior VP, Clinical Development & Medial Affairs Nick Pizzie, CPA, MBA, CFO Herriot Tabuteau, MD, CEO
| | Company Description | Axsome Therapeutics is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders. By focusing on this therapeutic area, Axsome is addressing significant and growing markets where current treatment options are limited or inadequate. Axsome’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which are being developed for multiple indications. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders. | |
|
|
|
|
|